Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Genasense Phase III Trial In Multiple Myeloma Fails

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Genta says it will analyze the trial data “in considerably more detail before making decisions regarding the Genasense program in myeloma.” News of the failed trial comes on the heels of a separate Phase III study of oblimersen in chronic lymphocytic leukemia that met its primary endpoint but failed to show a survival benefit.

You may also be interested in...



Genta Suffers Another Setback With Bcl-2 Inhibitor Genasense

Topline data from the firm’s Phase III study in treatment naive acute myelogenous leukemia patients fail to show survival benefit.

Genta Suffers Another Setback With Bcl-2 Inhibitor Genasense

Topline data from the firm’s Phase III study in treatment naive acute myelogenous leukemia patients fail to show survival benefit.

Genasense Gets Second Chance As Genta Completes Chronic Leukemia NDA

Genta hopes confirmatory trial to support accelerated approval will use different regimen combining Genasense with Rituxan and chemotherapy.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

See All
UsernamePublicRestriction

Register

PS058237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By